Research

The IMB nurtures an environment that fosters breakthrough science through collaboration, innovative ideas and taking calculated risk.

We push through the boundaries, go beyond the known, the safe and the normal, using cutting edge technologies to discover, transform and translate.

'Life-changing' psoriasis pill gets FDA approval

A breakthrough decades in the making has put Australian science on the global stage—delivering a game-changing, needle-free treatment for millions living with psoriasis.
Developed through a powerful collaboration between Johnson & Johnson and UQ spin-out Protagonist Therapeutics, the newly FDA-approved oral drug ICOTYDE (icotrokinra) offers patients a simpler, once-daily alternative to injections. Born out of research at Institute for Molecular Bioscience, the innovation highlights Australia’s growing influence in next-generation therapeutics.
For the 60–125 million people worldwide affected by psoriasis, this isn’t just a scientific milestone—it’s a life-changing shift toward more accessible, patient-friendly care, with the potential to unlock new treatments for a range of immune-related diseases.
Large-scale study shows why brain scans alone won’t diagnose depression — and what needs to change.

Can a brain scan reveal whether someone has depression?
From burgers to biomed, algae reinvents cell culture

As Australia becomes one of only three countries to approve cultivated meat for sale, researchers at The University of Queensland’s Institute for Molecular Bioscience (IMB) have made a discovery that could help the emerging industry scale sustainably and overcome one of its biggest hurdles: cost.